baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

QIAGEN NV/ NL0015001WM6 /

2024-06-25 4:35:06 PM	Chg. -0.040	Volume	Bid4:41:46 PM	Ask4:41:46 PM	Market Capitalization	Dividend Y.	P/E Ratio
38.930EUR	-0.10%	210 Turnover: 8,179.250	38.945Bid Size: 1,028	38.945Ask Size: 1,028	8.81 bill.EUR	-	-

GlobeNewswire 06-17 QIAGEN announces 2028 strategy for solid profitable growth

GlobeNewswire 06-13 QIAGEN’s software QCI Interpret accelerates clinical reporting turnaround time for high throughput N...

GlobeNewswire 06-12 QIAGEN publishes 2023 sustainability report, highlighting progress on ESG goals and commitment to su...

GlobeNewswire 06-11 QIAGEN launches new QIAcuity digital PCR assays for microbial applications, enhancing infectious dis...

GlobeNewswire 06-06 QIAGEN to discontinue NeuMoDx integrated PCR testing system, support customers during transition per...

GlobeNewswire 06-05 QIAGEN launches digital PCR Assay Design Tool for QIAcuity, expands customization capabilities of it...

GlobeNewswire 06-03 QIAGEN expands QIAstat-Dx syndromic testing menu in the U.S. with launch of molecular test to improv...

GlobeNewswire 05-30 QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global...

GlobeNewswire 05-29 QIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision ...

GlobeNewswire 05-22 deepull appoints Didier Deltort to its Board of Directors

GlobeNewswire 05-14 QIAGEN receives European IVDR certification for QIAGEN Clinical Insight Interpret, its medical devic...

GlobeNewswire 05-13 QIAGEN receives FDA clearance for QIAstat-Dx respiratory syndromic testing panel for fast and accura...

GlobeNewswire 05-07 QIAGEN partners with FBI to develop digital PCR assay for QIAcuity for use in forensics

GlobeNewswire 05-02 QIAGEN enhances bioinformatics workflows with new secondary analysis solution for oncology and inher...

GlobeNewswire 04-29 QIAGEN reports results for Q1 2024 ahead of outlook, on track to achieve full-year 2024 guidance

GlobeNewswire 04-25 deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ...

GlobeNewswire 04-24 QIAGEN expands tuberculosis portfolio with new NGS Panel to support real-time surveillance and comba...

GlobeNewswire 04-18 deepull appoints Kimberle Chapin, MD, as Chief Medical Officer and Wade Stevenson as Chief Marketing...

GlobeNewswire 04-09 QIAGEN N.V. to release results for Q1 2024 and hold webcast

GlobeNewswire 04-03 QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Ann...

GlobeNewswire 03-25 QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration a...

GlobeNewswire 03-18 QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosi...

GlobeNewswire 03-11 QIAGEN announces Form 20-F annual report filing for 2023 results

GlobeNewswire 02-27 QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery

QIAGEN NV/ NL0015001WM6 /

If you wish to receive reply to your feedback, please provide your email address.